Matthew J. Maurer, Ph.D. - Publications

Institution:
Johns Hopkins University, Baltimore, MD
Area:
s.cerevisiae, membrane biology, ABC transporters, protein degradation mechanisms

209 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Arushi Khurana, Mwangi R, Ansell SM, Habermann TM, Cerhan JR, Strouse C, Link BK, Wang Y, King RL, Macon WR, Villasboas JC, Witzig TE, Maurer MJ, Nowakowski GS. Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer Journal. 11: 133. PMID 34274939 DOI: 10.1038/s41408-021-00525-0  0.01
2021 Goldman ML, Mao JJ, Strouse CS, Chen W, Rupji M, Chen Z, Maurer MJ, Calzada O, Churnetski M, Flowers CR, Cerhan JR, Link BK, Thompson CA, Cohen JB. Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer. PMID 34157780 DOI: 10.1002/cncr.33660  0.01
2021 Goldman ML, Mao JJ, Strouse CS, Chen W, Rupji M, Chen Z, Maurer MJ, Calzada O, Churnetski M, Flowers CR, Cerhan JR, Link BK, Thompson CA, Cohen JB. Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer. PMID 34157780 DOI: 10.1002/cncr.33660  0.01
2021 Chihara D, Larson MC, Robinson DP, Thompson CA, Maurer MJ, Casulo C, Pophali P, Link BK, Habermann TM, Feldman AL, Flowers CR, Cerhan JR, Morton LM. Body mass index and survival of patients with lymphoma. Leukemia & Lymphoma. 1-8. PMID 34121594 DOI: 10.1080/10428194.2021.1929956  0.01
2021 Boddicker NJ, Larson MC, Castellino A, Herrmann J, Inwards DJ, Thanarajasingam G, Maurer MJ, Allmer C, Witzig TE, Nowakowski GS, Habermann TM, Villarraga H, Slager SL, Cerhan JR, Thompson CA. Anthracycline Treatment, Cardiovascular Risk Factors and the Cumulative Incidence of Cardiovascular Disease in a Cohort of Newly Diagnosed Lymphoma Patients from the Modern Treatment Era. American Journal of Hematology. PMID 33971040 DOI: 10.1002/ajh.26230  0.01
2021 Bataillard EJ, Cheah CY, Maurer MJ, Khurana A, Eyre TA, El-Galaly TC. Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. Blood Advances. 5: 2426-2437. PMID 33961018 DOI: 10.1182/bloodadvances.2021004665  0.01
2021 Khurana A, Maurer MJ. Reversing the restrictive trend in diffuse large B-cell lymphoma trial eligibility: it's time to open the gates! British Journal of Haematology. PMID 33851431 DOI: 10.1111/bjh.17433  0.01
2021 Oberg AL, Heinzen EP, Hou X, Al Hilli MM, Hurley RM, Wahner Hendrickson AE, Goergen KM, Larson MC, Becker MA, Eckel-Passow JE, Maurer MJ, Kaufmann SH, Haluska P, Weroha SJ. Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. Scientific Reports. 11: 8076. PMID 33850213 DOI: 10.1038/s41598-021-87470-x  0.01
2021 Yang LT, Boler A, Medina-Inojosa JR, Scott CG, Maurer MJ, Eleid MF, Enriquez-Sarano M, Tribouilloy C, Michelena HI. Aortic Stenosis Progression, Cardiac Damage, and Survival: Comparison Between Bicuspid and Tricuspid Aortic Valves. Jacc. Cardiovascular Imaging. PMID 33744153 DOI: 10.1016/j.jcmg.2021.01.017  0.01
2021 Le K, Wellik LE, Maurer MJ, McPhail ED, Witzig TE, Gupta M. JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis. Blood Cancer Journal. 11: 56. PMID 33712566 DOI: 10.1038/s41408-021-00447-x  0.01
2021 Maurer MJ, Jakobsen LH, Mwangi R, Schmitz N, Farooq U, Flowers CR, de Nully Brown P, Thompson CA, Frederiksen H, Cunningham D, Jørgensen J, Poeschel V, Nowakowski G, Seymour JF, Merli F, et al. R/R International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. American Journal of Hematology. PMID 33661547 DOI: 10.1002/ajh.26149  0.01
2021 Abeykoon JP, Hampel PJ, King RL, Wood AJ, Larson MC, Nowakowski KE, Zanwar SS, Dasari S, Ruan GJ, Ravindran A, Wellik LE, Paludo J, Link BK, Cerhan JR, Ansell SM, ... ... Maurer MJ, et al. The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. Haematologica. PMID 33657788 DOI: 10.3324/haematol.2020.278277  0.01
2021 Khurana A, Mwangi R, Nowakowski GS, Habermann TM, Ansell SM, LaPlant BR, Link BK, Cerhan JR, Maurer MJ, Witzig TE. Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001935. PMID 33529046 DOI: 10.1200/JCO.20.01935  0.01
2020 Banville AC, Wouters MCA, Oberg AL, Goergen KM, Maurer MJ, Milne K, Ashkani J, Field E, Ghesquiere C, Jones SJM, Block MS, Nelson BH. Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. Gynecologic Oncology. PMID 33342620 DOI: 10.1016/j.ygyno.2020.12.005  0.01
2020 Higgins A, Kim H, Harper L, Habermann TM, Nowakowski GS, Thompson CA, Johnston P, Witzig TE, Allmer C, Maurer MJ, Cerhan JR, Young JR, Thanarajasingam G. Testicular FDG-PET/CT Uptake Threshold in Aggressive Lymphomas. American Journal of Hematology. PMID 33338288 DOI: 10.1002/ajh.26073  0.01
2020 Krull JE, Wenzl K, Hartert KT, Manske MK, Sarangi V, Maurer MJ, Larson MC, Nowakowski GS, Ansell SM, McPhail E, Habermann TM, Link BK, King RL, Cerhan JR, Novak AJ. Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. Blood Cancer Journal. 10: 117. PMID 33168821 DOI: 10.1038/s41408-020-00382-3  0.01
2020 Sohani AR, Maurer MJ, Giri S, Pitcher B, Chadburn A, Said JW, Bartlett NL, Czuczman MS, Martin P, Rosenbaum CA, Jung SH, Leonard JP, Cheson BD, Hsi ED. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. The American Journal of Surgical Pathology. PMID 33136585 DOI: 10.1097/PAS.0000000000001609  0.01
2020 Pophali PA, Larson MC, Rosenthal AC, Robinson D, Habermann TM, Thanarajasingam G, Call T, Allmer C, Farooq U, Maurer MJ, Yost KJ, Cerhan JR, Thompson CA. The association of health behaviors with quality of life in lymphoma survivors. Leukemia & Lymphoma. 1-10. PMID 33047636 DOI: 10.1080/10428194.2020.1830389  0.01
2020 Hwang SR, Higgins A, Castillo Almeida NE, LaPlant B, Maurer MJ, Ansell SM, Witzig TE, Thanarajasingam G, Bennani NN. Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors. Leukemia & Lymphoma. 1-5. PMID 33021136 DOI: 10.1080/10428194.2020.1827250  0.01
2020 St-Pierre F, Broski SM, LaPlant BR, Maurer MJ, Ristow K, Thanarajasingam G, Macon WR, Habermann TM, Witzig TE. Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. The Oncologist. PMID 32319706 DOI: 10.1634/theoncologist.2019-0952  0.01
2020 Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum KA, LaCasce AS, Hsi ED, Liu YT, Scott DW, Hurd D, Ruppert AS, Hernandez-Ilizaliturri F, et al. Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403. American Journal of Hematology. PMID 32170769 DOI: 10.1002/ajh.25783  0.01
2020 Hartert KT, Wenzl K, Krull JE, Manske M, Sarangi V, Asmann Y, Larson MC, Maurer MJ, Slager S, Macon WR, King RL, Feldman AL, Gandhi AK, Link BK, Habermann TM, et al. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia. PMID 32139889 DOI: 10.1038/S41375-020-0766-4  0.01
2020 Harris RS, Serebrenik AA, Argyris P, Jarvis MC, Brown WL, Bazzaro M, Vogel RI, Erickson BK, Lee SH, Goergen KM, Maurer MJ, Oberg AL, Hou X, Weroha SJ, Kaufmann SH, et al. The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32060098 DOI: 10.1158/1078-0432.Ccr-19-2786  0.01
2020 Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, ... ... Maurer MJ, et al. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. British Journal of Haematology. PMID 32017050 DOI: 10.1111/bjh.16425  0.01
2020 Risueno A, Hagner PR, Towfic F, Fontanillo C, Djebbari A, Parker JS, Drew C, Nowakowski GS, Maurer MJ, Cerhan JR, Wei X, Ren Y, Lee CW, Couto S, Wang M, et al. Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. Blood. PMID 31977005 DOI: 10.1182/Blood.2019002414  0.01
2020 Pophali PA, Marinelli LM, Ketterling RP, Meyer RG, McPhail ED, Kurtin PJ, Mwangi R, Maurer MJ, Habermann T, King RL. High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease? Blood Cancer Journal. 10: 5. PMID 31932576 DOI: 10.1038/s41408-019-0271-z  0.01
2020 Pophali PA, Larson MC, Allmer C, Farooq U, Link BK, Maurer MJ, Cerhan JR, Thompson CA. Compliance with cancer screening and influenza vaccination guidelines in non-Hodgkin lymphoma survivors. Journal of Cancer Survivorship : Research and Practice. PMID 31897876 DOI: 10.1007/s11764-019-00846-x  0.01
2019 Clausen MR, Maurer MJ, Ulrichsen SP, Larsen TS, Himmelstrup B, Rønnov-Jessen D, Link BK, Feldman AL, Slager SL, Nowakowski GS, Thompson CA, Pedersen PT, Madsen J, Pedersen RS, Gørløv JS, et al. Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. Clinical Epidemiology. 11: 987-996. PMID 31814771 DOI: 10.2147/CLEP.S219595  0.01
2019 Torres D, Hou X, Bale L, Heinzen EP, Maurer MJ, Zanfagnin V, Oberg AL, Conover C, Weroha SJ. Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A. Plos One. 14: e0224564. PMID 31751381 DOI: 10.1371/journal.pone.0224564  0.01
2019 Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, et al. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Cancer. PMID 31714594 DOI: 10.1002/Cncr.32600  0.01
2019 Fama A, Larson MC, Link BK, Habermann TM, Feldman AL, Call TG, Ansell SM, Liebow M, Xiang J, Maurer MJ, Slager SL, Nowakowski GS, Stapleton JT, Cerhan JR. Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 31671178 DOI: 10.1093/Cid/Ciz940  0.01
2019 Maurer MJ. POD24 in MZL: a means to an end or an end point in itself? Blood. 134: 787-788. PMID 31488454 DOI: 10.1182/blood.2019002305  0.01
2019 Wang Y, Wenzl K, Manske MK, Asmann YW, Sarangi V, Greipp PT, Krull JE, Hartert K, He R, Feldman AL, Maurer MJ, Slager SL, Nowakowski GS, Habermann TM, Witzig TE, et al. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer Journal. 9: 73. PMID 31471540 DOI: 10.1038/S41408-019-0233-5  0.01
2019 Clay-Gilmour AI, Rishi AR, Goldin LR, Greenberg-Worisek AJ, Achenbach SJ, Rabe KG, Maurer MJ, Kay NE, Shanafelt TD, Call TG, Brice Weinberg J, Camp NJ, Cerhan JR, Leis J, Norman A, et al. Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood Cancer Journal. 9: 59. PMID 31383849 DOI: 10.1038/S41408-019-0220-X  0.01
2019 Wang Y, Link BK, Witzig TE, Maurer MJ, Allmer C, King RL, Feldman AL, Habermann TM, Ansell SM, Slager SL, Cerhan JR, Nowakowski GS. Impact of Concurrent Indolent Lymphoma on the Clinical Outcome of Newly Diagnosed Diffuse Large B-Cell Lymphoma. Blood. PMID 31350266 DOI: 10.1182/blood.2019000858  0.01
2019 Wang Y, Farooq U, Link BK, Larson MC, King RL, Maurer MJ, Allmer C, Hefazi M, Thompson CA, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Ansell SM, Cerhan JR, et al. Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900014. PMID 31170029 DOI: 10.1200/JCO.19.00014  0.01
2019 Wang Y, Maurer MJ, Larson MC, Allmer C, Feldman AL, Bennani NN, Thompson CA, Porrata LF, Habermann TM, Witzig TE, Ansell SM, Slager SL, Nowakowski GS, Cerhan JR. Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. British Journal of Haematology. PMID 31135975 DOI: 10.1111/bjh.15997  0.01
2019 St-Pierre F, Broski SM, LaPlant BR, Ristow K, Maurer MJ, Macon WR, Habermann TM, Ansell SM, Thompson CA, Micallef INM, Nowakowski GS, Witzig TE. Detection of Extranodal and Spleen Involvement by FDG-PET Imaging Predicts Adverse Survival in Untreated Follicular Lymphoma. American Journal of Hematology. PMID 31006875 DOI: 10.1002/ajh.25493  0.01
2019 Sibon D, Nguyen DP, Schmitz N, Suzuki R, Feldman AL, Gressin R, Lamant L, Weisenburger DD, Rosenwald A, Nakamura S, Ziepert M, Maurer MJ, Bast M, Armitage JO, Vose JM, et al. ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients. Haematologica. PMID 31004022 DOI: 10.3324/haematol.2018.213512  0.01
2019 Birdsell DN, Yaglom H, Rodriguez E, Engelthaler DM, Maurer M, Gaither M, Vinocur J, Weiss J, Terriquez J, Komatsu K, Ormsby ME, Gebhardt M, Solomon C, Nienstadt L, Williamson CHD, et al. Phylogenetic Analysis of Francisella tularensis Group A.II Isolates from 5 Patients with Tularemia, Arizona, USA, 2015-2017. Emerging Infectious Diseases. 25: 944-946. PMID 31002053 DOI: 10.3201/Eid2505.180363  0.01
2019 Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, et al. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801994. PMID 30939090 DOI: 10.1200/Jco.18.01994  0.01
2019 Tracy SI, Larson MC, Feldman AL, Maurer MJ, Novak AJ, Slager SL, Villasboas JC, Allmer C, Habermann TM, Farooq U, Syrbu S, Cerhan JR, Link BK. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. American Journal of Hematology. PMID 30916801 DOI: 10.1002/ajh.25473  0.01
2019 Ellin F, Maurer MJ, Srour L, Farooq U, Jerkeman M, Connors JM, Smedby KE, Bennani NN, Ansell SM, Slack GW, Cerhan JR, Relander T, Feldman AL, Savage KJ. Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas. British Journal of Haematology. PMID 30859549 DOI: 10.1111/bjh.15859  0.01
2019 Wang Y, Habermann TM, Wang SS, Maurer MJ, Sarangi V, Link BK, Feldman AL, Inwards DJ, Witzig TE, Cozen W, Rothman N, Asmann Y, Slager SL, Cerhan JR. Host Genetic Variation in the TNF and NF-ĸB Pathways and Overall Survival in Mantle Cell Lymphoma: A Discovery and Replication Study. American Journal of Hematology. PMID 30815899 DOI: 10.1002/Ajh.25451  0.01
2019 Hurley RM, Wahner Hendrickson AE, Visscher DW, Ansell P, Harrell MI, Wagner JM, Negron V, Goergen KM, Maurer MJ, Oberg AL, Meng XW, Flatten KS, De Jonge MJA, Van Herpen CD, Gietema JA, et al. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer. Gynecologic Oncology. PMID 30686551 DOI: 10.1016/J.Ygyno.2019.01.015  0.01
2019 Maurer MJ, Habermann TM. Reply to the letter to the editor ‘Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting’ by van der Galiën et al. Annals of Oncology. 30: 153-153. PMID 30395156 DOI: 10.1093/Annonc/Mdy492  0.01
2018 Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Fakhri B, Reddy P, Smith SD, Mukhija D, Jagadeesh D, Desai A, Pablo Alderuccio J, et al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphoma. British Journal of Haematology. PMID 30575016 DOI: 10.1111/bjh.15720  0.01
2018 Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA, Traverse-Glehen A, Feldman AL, Allmer C, Slager SL, Ansell SM, Habermann TM, Bachy E, Cerhan JR, Salles G. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800400. PMID 30481079 DOI: 10.1200/JCO.18.00400  0.01
2018 Mackrides N, Chapman J, Larson MC, Ramos JC, Toomey N, Lin P, Maurer MJ, Rafaelle M, Tan Y, Ikpatt O, Syrbu S, Ansell SM, Habermann TM, Link BK, Feldman AL, et al. Prevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma. American Journal of Hematology. PMID 30474261 DOI: 10.1002/ajh.25357  0.01
2018 Han JJ, O'byrne M, Stenson MJ, Maurer MJ, Wellik LE, Feldman AL, McPhail ED, Witzig TE, Gupta M. Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. Blood Cancer Journal. 8: 110. PMID 30420593 DOI: 10.1038/s41408-018-0138-8  0.01
2018 Kofman A, Rahav G, Yazzie D, Shorty H, Yaglom HD, Peterson D, Peek-Bullock M, Choi MJ, Wieder-Finesod A, Klena JD, Venkat H, Chiang CF, Knust B, Gaither M, Maurer M, et al. Notes from the Field: Exported Case of Sin Nombre Hantavirus Pulmonary Syndrome - Israel, 2017. Mmwr. Morbidity and Mortality Weekly Report. 67: 1129. PMID 30307906 DOI: 10.15585/Mmwr.Mm6740A5  0.01
2018 Wenzl K, Manske MK, Sarangi V, Asmann YW, Greipp PT, Schoon HR, Braggio E, Maurer MJ, Feldman AL, Witzig TE, Slager SL, Ansell SM, Cerhan JR, Novak AJ. Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma. Blood Cancer Journal. 8: 97. PMID 30301877 DOI: 10.1038/S41408-018-0130-3  0.01
2018 Thanarajasingam G, Maurer MJ, Habermann TM, Nowakowski GS, Bennani-Baiti NN, Thompson CA, Cerhan JR, Witzig TE. Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker? Nutrition and Cancer. 1-3. PMID 30235018 DOI: 10.1080/01635581.2018.1502328  0.01
2018 Pophali PA, Ip A, Larson MC, Rosenthal AC, Maurer MJ, Flowers CR, Link BK, Farooq U, Feldman AL, Allmer C, Slager SL, Witzig TE, Habermann TM, Cohen JB, Cerhan JR, et al. The Association of Physical Activity Before and After Lymphoma Diagnosis with Survival Outcomes. American Journal of Hematology. PMID 30230581 DOI: 10.1002/ajh.25288  0.01
2018 Kleinstern G, Maurer MJ, Liebow M, Habermann TM, Koff JL, Allmer C, Witzig TE, Nowakowski GS, Micallef IN, Johnston PB, Inwards DJ, Thompson CA, Feldman AL, Link BK, Flowers C, et al. History of autoimmune conditions and lymphoma prognosis. Blood Cancer Journal. 8: 73. PMID 30069001 DOI: 10.1038/s41408-018-0105-4  0.01
2018 McPhail ED, Maurer MJ, Macon WR, Feldman AL, Kurtin PJ, Ketterling RP, Vaidya R, Cerhan JR, Ansell SM, Porrata LF, Nowakowski GS, Witzig TE, Habermann TM. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica. PMID 29903764 DOI: 10.3324/haematol.2018.190157  0.01
2018 Thompson CA, Yost KJ, Maurer MJ, Allmer C, Farooq U, Habermann TM, Inwards DJ, Macon WR, Link BK, Rosenthal AC, Cerhan JR. Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematological Oncology. PMID 29862550 DOI: 10.1002/hon.2522  0.01
2018 Fama A, Xiang J, Link BK, Allmer C, Klinzman D, Feldman AL, Nowakowski GS, Liebow M, Larson MC, Maurer MJ, Ansell SM, Novak AJ, Asmann YW, Slager SL, Call TG, et al. Human Pegivirus infection and lymphoma risk and prognosis: a North American study. British Journal of Haematology. PMID 29808922 DOI: 10.1111/Bjh.15416  0.01
2018 Kurokawa C, Iankov ID, Anderson SK, Aderca I, Leontovich AA, Maurer MJ, Oberg AL, Schroeder MA, Giannini C, Greiner SM, Becker MA, Thompson EA, Haluska P, Jentoft ME, Parney IF, et al. Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. Journal of the National Cancer Institute. PMID 29788332 DOI: 10.1093/Jnci/Djy033  0.01
2018 Maurer MJ, Ghesquières H, Link BK, Jais JP, Habermann TM, Thompson CA, Haioun C, Allmer C, Johnston PB, Delarue R, Micallef IN, Peyrade F, Inwards DJ, Ketterer N, Farooq U, et al. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017765198. PMID 29672223 DOI: 10.1200/JCO.2017.76.5198  0.01
2018 Bachy E, Maurer MJ, Habermann TM, Gelas-Dore B, Maucort-Boulch D, Estell JA, Van den Neste E, Bouabdallah R, Gyan E, Feldman AL, Bargay J, Delmer A, Slager SL, da Silva MG, Fitoussi O, et al. A simplified scoring system in follicular lymphoma treated initially with immunochemotherapy. Blood. PMID 29666118 DOI: 10.1182/blood-2017-11-816405  0.01
2018 Widmer RJ, Maurer MJ, Nayar VR, Aase LA, Wald JT, Kotsenas AL, Timimi FK, Harper CM, Pruthi S. Online Physician Reviews Do Not Reflect Patient Satisfaction Survey Responses. Mayo Clinic Proceedings. 93: 453-457. PMID 29622095 DOI: 10.1016/j.mayocp.2018.01.021  0.01
2018 Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, Rajkumar SV. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer Journal. 8: 26. PMID 29531285 DOI: 10.1038/S41408-018-0065-8  0.01
2018 El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, ... ... Maurer MJ, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. European Journal of Cancer (Oxford, England : 1990). 93: 57-68. PMID 29477102 DOI: 10.1016/j.ejca.2018.01.073  0.01
2017 Tracy SI, Habermann TM, Feldman AL, Maurer MJ, Dogan A, Perepu US, Syrbu S, Ansell SM, Thompson CA, Weiner GJ, Nowakowski GS, Allmer C, Slager SL, Witzig TE, Cerhan JR, et al. Outcomes among US patients with diffuse large B cell lymphoma are independent of tumor Epstein Barr virus positivity or immunosuppression. Haematologica. PMID 29170255 DOI: 10.3324/haematol.2017.176511  0.01
2017 Maurer MJ, Ellin F, Srour L, Jerkeman M, Bennani NN, Connors JM, Slack GW, Smedby KE, Ansell SM, Link BK, Cerhan JR, Relander T, Savage KJ, Feldman AL. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017738195. PMID 29072976 DOI: 10.1200/JCO.2017.73.8195  0.01
2017 Cerhan JR, Link BK, Habermann TM, Maurer MJ, Feldman AL, Syrbu SI, Thompson CA, Farooq U, Novak AJ, Slager SL, Allmer C, Lunde JJ, Macon WR, Inwards DJ, Johnston PB, et al. Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. International Journal of Epidemiology. PMID 29025017 DOI: 10.1093/ije/dyx119  0.01
2017 Thanarajasingam G, Maurer MJ, Farooq U, Johnston PB, Thompson CA, Bennani NN, Ansell SM, Porrata LF, Macon WR, Syrbu SI, Cerhan JR, Habermann TM, Link BK, Witzig TE, Nowakowski GS. Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. British Journal of Haematology. PMID 28961306 DOI: 10.1111/bjh.14922  0.01
2017 Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. PMID 28774879 DOI: 10.1182/Blood-2017-03-769620  0.01
2017 Mehner C, Oberg AL, Goergen KM, Kalli KR, Maurer MJ, Nassar A, Goode EL, Keeney GL, Jatoi A, Radisky DC, Radisky ES. EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. Genes & Cancer. 8: 589-599. PMID 28740577 DOI: 10.18632/Genesandcancer.142  0.01
2017 Leal AD, Allmer C, Maurer MJ, Shanafelt TD, Cerhan JR, Link BK, Thompson CA. Variability of performance status assessment between patients with hematologic malignancies and their physicians. Leukemia & Lymphoma. 1-7. PMID 28718335 DOI: 10.1080/10428194.2017.1347930  0.01
2017 Farooq U, Maurer MJ, Thompson CA, Thanarajasingam G, Inwards DJ, Micallef I, Macon W, Syrbu S, Lin T, Lin Y, Ansell SM, Nowakowski GS, Habermann TM, Cerhan JR, Link BK. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. British Journal of Haematology. PMID 28653407 DOI: 10.1111/bjh.14813  0.01
2017 Park JY, Foley TA, Bonnichsen CR, Maurer MJ, Goergen KM, Nkomo VT, Enriquez-Sarano M, Williamson EE, Michelena HI. Transthoracic Echocardiography versus Computed Tomography for Ascending Aortic Measurements in Patients with Bicuspid Aortic Valve. Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography. PMID 28501375 DOI: 10.1016/j.echo.2017.03.006  0.01
2017 Binder M, O'Byrne MM, Maurer MJ, Ansell S, Feldman AL, Cerhan J, Novak A, Porrata LF, Markovic S, Link BK, Witzig TE. Associations between Elevated Pre-treatment Serum Cytokines and Peripheral Blood Cellular Markers of Immunosuppression in Patients with Lymphoma. American Journal of Hematology. PMID 28383112 DOI: 10.1002/ajh.24758  0.01
2017 Pham AQ, Broski SM, Habermann TM, Jevremovic D, Wiseman GA, Feldman AL, Maurer MJ, Ristow KM, Witzig TE. Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma - tissue remains the issue. Leukemia & Lymphoma. 1-7. PMID 28290723 DOI: 10.1080/10428194.2017.1300891  0.01
2017 Wang C, Armasu SM, Kalli KR, Maurer MJ, Heinzen EP, Keeney G, Cliby WA, Oberg AL, Kaufmann SH, Goode EL. Pooled clustering of high-grade serous ovarian cancer gene expression leads to novel consensus subtypes associated with survival and surgical outcomes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28280090 DOI: 10.1158/1078-0432.Ccr-17-0246  0.01
2017 Rin Kim S, Skerker JM, Iok Kong I, Kim H, Maurer MJ, Zhang GC, Peng D, Wei N, Arkin AP, Jin YS. Metabolic engineering of a haploid strain derived from a triploid industrial yeast for producing cellulosic ethanol. Metabolic Engineering. PMID 28216106 DOI: 10.1016/J.Ymben.2017.02.006  0.01
2017 Kommoss S, Winterhoff B, Oberg A, Konecny GE, Wang C, Riska SM, Fan JB, Maurer MJ, April C, Shridhar V, Kommoss F, du Bois A, Hilpert F, Mahner S, Baumann K, et al. Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28159814 DOI: 10.1158/1078-0432.CCR-16-2196  0.01
2016 Maurer MJ, Allmer C, Ansell SM, Farooq U, Habermann TM, Link BK, Witzig TE, Yost KJ, Cerhan JR, Thompson CA. Health behaviors in survivors of aggressive NHL. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 236. PMID 28151166 DOI: 10.1200/Jco.2016.34.3_Suppl.236  0.01
2016 Maurer MJ, Sutardja L, Pinel D, Bauer S, Muehlbauer AL, Ames TD, Skerker JM, Arkin AP. QTL-guided metabolic engineering of a complex trait. Acs Synthetic Biology. PMID 27936603 DOI: 10.1021/Acssynbio.6B00264  0.01
2016 Ghesquières H, Larrabee BR, Casasnovas O, Maurer MJ, McKay JD, Ansell SM, Montgomery D, Asmann YW, Farrell K, Verney A, Slager SL, Allmer C, Perrot A, Delarue R, Habermann TM, et al. A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts. British Journal of Haematology. PMID 27716907 DOI: 10.1111/Bjh.14306  0.01
2016 Maurer MJ, Bachy E, Ghesquières H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Clément C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, et al. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. American Journal of Hematology. PMID 27465588 DOI: 10.1002/ajh.24492  0.01
2016 Ghesquières H, Larrabee BR, Haioun C, Link BK, Verney A, Slager SL, Ketterer N, Ansell SM, Delarue R, Maurer MJ, Fitoussi O, Habermann TM, Peyrade F, Dogan A, Molina TJ, et al. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. Hematological Oncology. PMID 27282998 DOI: 10.1002/hon.2305  1
2016 Maurer MJ, Spear ED, Yu AT, Lee EJ, Shahzad S, Michaelis S. Degradation Signals for Ubiquitin-Proteasome Dependent Cytosolic Protein Quality Control (CytoQC) in Yeast. G3 (Bethesda, Md.). PMID 27172186 DOI: 10.1534/G3.116.027953  0.01
2016 Parry HM, Damery S, Hudson C, Maurer MJ, Cerhan JR, Pachnio A, Begum J, Slager SL, Fegan C, Man S, Pepper C, Shanafelt TD, Pratt G, Moss PA. Cytomegalovirus infection does not impact on survival or time to first treatment in patients with Chronic Lymphocytic Leukaemia. American Journal of Hematology. PMID 27124884 DOI: 10.1002/ajh.24403  0.01
2016 Oh EJ, Skerker JM, Kim SR, Wei N, Turner TL, Maurer MJ, Arkin AP, Jin YS. Gene amplification on demand accelerates cellobiose utilization in engineered Saccharomyces cerevisiae. Applied and Environmental Microbiology. PMID 27084006 DOI: 10.1128/Aem.00410-16  1
2016 Leonard B, Starrett GJ, Maurer MJ, Oberg A, Van Bockstal M, Van Dorpe J, De Wever O, Helleman J, Sieuwerts AM, Berns EM, Martens JW, Anderson B, Brown WL, Kalli KR, Kaufmann SH, et al. APOBEC3G expression correlates with T cell infiltration and improved clinical outcomes in high-grade serous ovarian carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27016308 DOI: 10.1158/1078-0432.Ccr-15-2910  0.01
2015 Maurer MJ, Jais JP, Ghesquières H, Witzig TE, Hong F, Haioun C, Thompson CA, Thieblemont C, Micallef IN, Porrata LF, Ribrag V, Nowakowski GS, Casanovas O, Bologna S, Morschhauser F, et al. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large b-cell lymphoma. American Journal of Hematology. PMID 26492520 DOI: 10.1002/ajh.24223  1
2015 Gupta M, Stenson M, O'Byrne M, Maurer MJ, Habermann T, Cerhan JR, Weiner GW, Witzig TE. Comprehensive Serum Cytokine Analysis Identifies IL-1RA and soluble IL-2Rα as Predictors of Event Free Survival in T-cell lymphoma. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. PMID 26487586 DOI: 10.1093/annonc/mdv486  1
2015 Zhang S, Skerker JM, Rutter CD, Maurer MJ, Arkin AP, Rao CV. Engineering Rhodosporidium toruloides for increased lipid production. Biotechnology and Bioengineering. PMID 26479039 DOI: 10.1002/Bit.25864  1
2015 Ghesquieres H, Slager SL, Jardin F, Veron AS, Asmann YW, Maurer MJ, Fest T, Habermann TM, Bene MC, Novak AJ, Mareschal S, Haioun C, Lamy T, Ansell SM, Tilly H, et al. Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26460308 DOI: 10.1200/Jco.2014.60.2573  1
2015 Mehner C, Oberg AL, Kalli KR, Nassar A, Hockla A, Pendlebury D, Cichon MA, Goergen KM, Maurer MJ, Goode EL, Keeney GL, Jatoi A, Sahin-Tóth M, Copland JA, Radisky DC, et al. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. Oncotarget. 6: 35737-35754. PMID 26437224 DOI: 10.18632/Oncotarget.5927  1
2015 Novak AJ, Asmann YW, Maurer MJ, Wang C, Slager SL, Hodge LS, Manske M, Price-Troska T, Yang ZZ, Zimmermann MT, Nowakowski GS, Ansell SM, Witzig TE, McPhail E, Ketterling R, et al. Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma. Blood Cancer Journal. 5: e346. PMID 26314988 DOI: 10.1038/Bcj.2015.69  1
2015 Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, Cunningham JM, Odunsi K, Hartmann LC, Kalli KR, Oberg AL, Goode EL. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. Cancer Immunology, Immunotherapy : Cii. PMID 26298430 DOI: 10.1007/S00262-015-1753-X  0.01
2015 Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2516-22. PMID 26124482 DOI: 10.1200/JCO.2014.59.7534  1
2015 Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. American Journal of Hematology. 90: 790-5. PMID 26096944 DOI: 10.1002/ajh.24086  0.01
2015 Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, Friedberg JW, Zelenetz AD, Maurer MJ, Cerhan JR, Flowers CR. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. British Journal of Haematology. 170: 85-95. PMID 25851937 DOI: 10.1111/bjh.13399  1
2015 Demosthenous C, Han JJ, Stenson MJ, Maurer MJ, Wellik LE, Link B, Hege K, Dogan A, Sotomayor E, Witzig T, Gupta M. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. Oncotarget. 6: 9488-501. PMID 25839159 DOI: 10.18632/Oncotarget.3378  0.01
2015 Boddicker RL, Kip NS, Xing X, Zeng Y, Yang ZZ, Lee JH, Almada LL, Elsawa SF, Knudson RA, Law ME, Ketterling RP, Cunningham JM, Wu Y, Maurer MJ, O'Byrne MM, et al. The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF-κB positive feedback loop in peripheral T-cell lymphoma. Blood. 125: 3118-27. PMID 25833963 DOI: 10.1182/Blood-2014-05-578575  1
2015 Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Link BK. Reply to V. Pitini et al and L.J. Costa. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1625-6. PMID 25800767 DOI: 10.1200/JCO.2014.60.5535  1
2015 Block MS, Maurer MJ, Goergen K, Kalli KR, Erskine CL, Behrens MD, Oberg AL, Knutson KL. Plasma immune analytes in patients with epithelial ovarian cancer. Cytokine. 73: 108-13. PMID 25743245 DOI: 10.1016/J.Cyto.2015.01.035  1
2015 Bakkum-Gamez JN, Wentzensen N, Maurer MJ, Hawthorne KM, Voss JS, Kroneman TN, Famuyide AO, Clayton AC, Halling KC, Kerr SE, Cliby WA, Dowdy SC, Kipp BR, Mariani A, Oberg AL, et al. Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecologic Oncology. 137: 14-22. PMID 25677060 DOI: 10.1016/J.Ygyno.2015.01.552  1
2015 Wahner Hendrickson AE, Hawthorne KM, Goode EL, Kalli KR, Goergen KM, Bakkum-Gamez JN, Cliby WA, Keeney GL, Visscher DW, Tarabishy Y, Oberg AL, Hartmann LC, Maurer MJ. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. Gynecologic Oncology. 137: 77-85. PMID 25620544 DOI: 10.1016/j.ygyno.2015.01.539  0.01
2015 Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H, Meng XW, Cerhan JR, Slager SL, Macon WR, Habermann TM, et al. BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood. 125: 658-67. PMID 25452615 DOI: 10.1182/Blood-2014-04-571786  1
2015 Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, LeBlanc M, Cerhan JR, Novak A, Ansell SM. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood. 125: 992-8. PMID 25422100 DOI: 10.1182/Blood-2014-06-583369  0.01
2015 Galanis E, Atherton PJ, Maurer MJ, Knutson KL, Dowdy SC, Cliby WA, Haluska P, Long HJ, Oberg A, Aderca I, Block MS, Bakkum-Gamez J, Federspiel MJ, Russell SJ, Kalli KR, et al. Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Research. 75: 22-30. PMID 25398436 DOI: 10.1158/0008-5472.Can-14-2533  1
2015 Rausch Osian S, Leal AD, Allmer C, Maurer MJ, Nowakowski G, Inwards DJ, Macon WR, Ehlers SL, Weiner GJ, Habermann TM, Cerhan JR, Thompson CA. Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors. Leukemia & Lymphoma. 56: 434-9. PMID 24745936 DOI: 10.3109/10428194.2014.916803  1
2015 Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW, Press O, LeBlanc M, Cerhan JR, Novak A, Ansell SM. Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma Blood. 125: 992-998. DOI: 10.1182/blood-2014-06-583369  1
2015 Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, Cunningham JM, Odunsi K, Hartmann LC, Kalli KR, Oberg AL, Goode EL. Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer Cancer Immunology, Immunotherapy. DOI: 10.1007/s00262-015-1753-x  1
2015 Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011 American Journal of Hematology. 90: 790-795. DOI: 10.1002/ajh.24086  1
2015 Demosthenous C, Han JJ, Stenson MJ, Maurer MJ, Wellik LE, Link B, Hege K, Dogan A, Sotomayor E, Witzig T, Gupta M. Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma Oncotarget. 6: 9488-9501.  1
2014 Asmann YW, Maurer MJ, Wang C, Sarangi V, Ansell SM, Feldman AL, Nowakowski GS, Manske M, Price-Troska T, Yang ZZ, Slager SL, Habermann TM, Cerhan JR, Novak AJ. Genetic diversity of newly diagnosed follicular lymphoma. Blood Cancer Journal. 4: e256. PMID 25360902 DOI: 10.1038/Bcj.2014.80  1
2014 Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Biron P, Ansell SM, Chassagne-Clément C, Inwards DJ, Gargi T, Johnston PB, Nicolas-Virelizier E, Macon WR, Peix M, Micallef IN, Sebban C, et al. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3506-12. PMID 25267745 DOI: 10.1200/JCO.2014.55.7561  1
2014 Witzig TE, Maurer MJ, Habermann TM, Link BK, Micallef INM, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Markovic SN, Johnston PB, Lin Y, Thompson C, Gupta M, et al. Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B- and T-cell non-Hodgkin lymphoma American Journal of Hematology. 89: 1116-1120. PMID 25228125 DOI: 10.1002/ajh.23839  1
2014 Sonbol MB, Maurer MJ, Stenson MJ, Allmer C, LaPlant BR, Weiner GJ, Macon WR, Cerhan JR, Witzig TE, Gupta M. Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. American Journal of Hematology. 89: E223-7. PMID 25164110 DOI: 10.1002/ajh.23838  1
2014 Ryan OW, Skerker JM, Maurer MJ, Li X, Tsai JC, Poddar S, Lee ME, DeLoache W, Dueber JE, Arkin AP, Cate JH. Selection of chromosomal DNA libraries using a multiplex CRISPR system. Elife. 3. PMID 25139909 DOI: 10.7554/Elife.03703  1
2014 Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, Sidhu JS, Hsi ED, Karikehalli S, Jiang L, Vasmatzis G, Gibson SE, Ondrejka S, Nicolae A, Grogg KL, ... ... Maurer MJ, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 124: 1473-80. PMID 24894770 DOI: 10.1182/Blood-2014-04-571091  1
2014 Wang C, Evans JM, Bhagwate AV, Prodduturi N, Sarangi V, Middha M, Sicotte H, Vedell PT, Hart SN, Oliver GR, Kocher JP, Maurer MJ, Novak AJ, Slager SL, Cerhan JR, et al. PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. Bioinformatics (Oxford, England). 30: 2678-80. PMID 24876377 DOI: 10.1093/Bioinformatics/Btu363  1
2014 Charbonneau B, Moysich KB, Kalli KR, Oberg AL, Vierkant RA, Fogarty ZC, Block MS, Maurer MJ, Goergen KM, Fridley BL, Cunningham JM, Rider DN, Preston C, Hartmann LC, Lawrenson K, et al. Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome. Cancer Immunology Research. 2: 332-40. PMID 24764580 DOI: 10.1158/2326-6066.Cir-13-0136  1
2014 Gustafson HL, Yao S, Goldman BH, Lee K, Spier CM, LeBlanc ML, Rimsza LM, Cerhan JR, Habermann TM, Link BK, Maurer MJ, Slager SL, Persky DO, Miller TP, Fisher RI, et al. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. American Journal of Hematology. 89: 639-45. PMID 24633940 DOI: 10.1002/Ajh.23709  1
2014 Hsi ED, Said J, Macon WR, Rodig SJ, Ondrejka SL, Gascoyne RD, Morgan EA, Dorfman DM, Maurer MJ, Dogan A. Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project. The American Journal of Surgical Pathology. 38: 768-75. PMID 24618604 DOI: 10.1182/Blood.V120.21.1545.1545  1
2014 Maurer MJ, Ghesquières H, Jais JP, Witzig TE, Haioun C, Thompson CA, Delarue R, Micallef IN, Peyrade F, Macon WR, Jo Molina T, Ketterer N, Syrbu SI, Fitoussi O, Kurtin PJ, et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1066-73. PMID 24550425 DOI: 10.1200/JCO.2013.51.5866  1
2014 Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1288-97. PMID 24398046 DOI: 10.1158/1078-0432.Ccr-13-2611  1
2014 Witzig TE, Maurer MJ, Stenson MJ, Allmer C, Macon W, Link B, Katzmann JA, Gupta M. Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein-10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. American Journal of Hematology. 89: 417-22. PMID 24382707 DOI: 10.1002/ajh.23658  1
2014 Ryan OW, Skerker JM, Maurer MJ, Li X, Tsai JC, Poddar S, Lee ME, DeLoache W, Dueber JE, Arkin AP, Cate JH. Author response: Selection of chromosomal DNA libraries using a multiplex CRISPR system Elife. DOI: 10.7554/Elife.03703.012  0.01
2014 Wahner Hendrickson AE, Hawthorne KM, Goode EL, Kalli KR, Goergen KM, Bakkum-Gamez JN, Cliby WA, Keeney GL, Visscher DW, Tarabishy Y, Oberg AL, Hartmann LC, Maurer MJ. Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic Gynecologic Oncology. DOI: 10.1016/j.ygyno.2015.01.539  1
2013 Maurer MJ, Schellekens RC, Wutzke KD, Stellaard F. Isotope-labelled urea to test colon drug delivery devices in vivo: principles, calculations and interpretations. Isotopes in Environmental and Health Studies. 49: 473-91. PMID 24313370 DOI: 10.1080/10256016.2013.803099  0.01
2013 Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL. The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. Plos One. 8: e80063. PMID 24244610 DOI: 10.1371/Journal.Pone.0080063  1
2013 Leonard B, Hart SN, Burns MB, Carpenter MA, Temiz NA, Rathore A, Vogel RI, Nikas JB, Law EK, Brown WL, Li Y, Zhang Y, Maurer MJ, Oberg AL, Cunningham JM, et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Research. 73: 7222-31. PMID 24154874 DOI: 10.1158/0008-5472.Can-13-1753  1
2013 Marri PR, Hodge LS, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Cerhan JR, Novak AJ, Ansell SM. Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6812-9. PMID 24141626 DOI: 10.1158/1078-0432.CCR-13-1879  1
2013 Ghesquières H, Maurer MJ, Casasnovas O, Ansell SM, Larrabee BR, Lech-Maranda E, Novak AJ, Borrel AL, Slager SL, Brice P, Allmer C, Brion A, Ziesmer SC, Morschhauser F, Habermann TM, et al. Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts. Cytokine. 64: 523-31. PMID 24008079 DOI: 10.1016/j.cyto.2013.08.002  1
2013 Cicek MS, Maurer MJ, Goode EL. Survival prediction based on inherited gene variation analysis. Methods in Molecular Biology (Clifton, N.J.). 1049: 53-64. PMID 23913208 DOI: 10.1007/978-1-62703-547-7_5  1
2013 Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Habermann TM, Cerhan JR. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3272-8. PMID 23897955 DOI: 10.1200/JCO.2012.48.3990  1
2013 Carlson AM, Maurer MJ, Goergen KM, Kalli KR, Erskine CL, Behrens MD, Knutson KL, Block MS. Utility of progranulin and serum leukocyte protease inhibitor as diagnostic and prognostic biomarkers in ovarian cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 1730-5. PMID 23878295 DOI: 10.1158/1055-9965.Epi-12-1368  1
2013 Charbonneau B, Wang AH, Maurer MJ, Asmann YW, Zent CS, Link BK, Ansell SM, Weiner GJ, Ozsan N, Feldman AL, Witzig TE, Cunningham JM, Dogan A, Habermann TM, Slager SL, et al. CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. Cancer Immunology, Immunotherapy : Cii. 62: 1475-84. PMID 23812490 DOI: 10.1007/S00262-013-1452-4  1
2013 Vaidya R, Habermann TM, Donohue JH, Ristow KM, Maurer MJ, Macon WR, Colgan JP, Inwards DJ, Ansell SM, Porrata LF, Micallef IN, Johnston PB, Markovic SN, Thompson CA, Nowakowski GS, et al. Bowel perforation in intestinal lymphoma: incidence and clinical features. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 2439-43. PMID 23704194 DOI: 10.1093/annonc/mdt188  1
2013 Witzig TE, Wiseman GA, Maurer MJ, Habermann TM, Micallef IN, Nowakowski GS, Ansell SM, Colgan JP, Inwards DJ, Porrata LF, Link BK, Zent CS, Johnston PB, Shanafelt TD, Allmer C, et al. A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. American Journal of Hematology. 88: 589-93. PMID 23619698 DOI: 10.1002/Ajh.23460  1
2013 Ghesquières H, Dogan A, Link BK, Maurer MJ, Cunningham JM, Novak AJ, Larrabee BR, Slager SL, Allmer C, Habermann TM, Ansell SM, Cerhan JR. FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. Leukemia & Lymphoma. 54: 2571-3. PMID 23597143 DOI: 10.3109/10428194.2013.796048  1
2013 Maurer MJ. The potential of serum light chains in diffuse large B-cell lymphoma. Leukemia & Lymphoma. 54: 1857-8. PMID 23517591 DOI: 10.3109/10428194.2013.788700  1
2013 Goode EL, DeRycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, et al. Inherited variants in regulatory T cell genes and outcome of ovarian cancer. Plos One. 8: e53903. PMID 23382860 DOI: 10.1371/Journal.Pone.0053903  1
2013 Yost KJ, Thompson CA, Eton DT, Allmer C, Ehlers SL, Habermann TM, Shanafelt TD, Maurer MJ, Slager SL, Link BK, Cerhan JR. The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma. 54: 290-7. PMID 22799432 DOI: 10.3109/10428194.2012.711830  1
2012 Gupta M, Maurer MJ, Wellik LE, Law ME, Han JJ, Ozsan N, Micallef IN, Dogan A, Witzig TE. Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. Blood. 120: 4400-6. PMID 23018644 DOI: 10.1182/blood-2012-05-428466  1
2012 Charbonneau B, Maurer MJ, Ansell SM, Slager SL, Fredericksen ZS, Ziesmer SC, Macon WR, Habermann TM, Witzig TE, Link BK, Cerhan JR, Novak AJ. Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. Cytokine. 60: 882-9. PMID 23010502 DOI: 10.1016/j.cyto.2012.08.028  1
2012 Charbonneau B, Maurer MJ, Fredericksen ZS, Zent CS, Link BK, Novak AJ, Ansell SM, Weiner GJ, Wang AH, Witzig TE, Dogan A, Slager SL, Habermann TM, Cerhan JR. Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. American Journal of Hematology. 87: 880-5. PMID 22718493 DOI: 10.1002/ajh.23273  1
2012 Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK, Witzig TE, Macon WR, Dogan A, Cerhan JR, Novak AJ. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. American Journal of Hematology. 87: 865-9. PMID 22674570 DOI: 10.1002/ajh.23259  1
2012 Gibson TM, Wang SS, Cerhan JR, Maurer MJ, Hartge P, Habermann TM, Davis S, Cozen W, Lynch CF, Severson RK, Rothman N, Chanock SJ, Morton LM. Inherited genetic variation and overall survival following follicular lymphoma. American Journal of Hematology. 87: 724-6. PMID 22473939 DOI: 10.1002/Ajh.23184  1
2012 Maurer MJ, Schellekens RC, Wutzke KD, Dijkstra G, Woerdenbag HJ, Frijlink HW, Kosterink JG, Stellaard F. A non-invasive, low-cost study design to determine the release profile of colon drug delivery systems: a feasibility study. Pharmaceutical Research. 29: 2070-8. PMID 22422322 DOI: 10.1007/s11095-012-0735-3  1
2012 Braggio E, Dogan A, Keats JJ, Chng WJ, Huang G, Matthews JM, Maurer MJ, Law ME, Bosler DS, Barrett M, Lossos IS, Witzig TE, Fonseca R. Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 25: 651-60. PMID 22301699 DOI: 10.1038/Modpathol.2011.213  1
2012 Cerhan JR, Natkunam Y, Morton LM, Maurer MJ, Asmann Y, Habermann TM, Vasef MA, Cozen W, Lynch CF, Allmer C, Slager SL, Lossos IS, Chanock SJ, Rothman N, Hartge P, et al. LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. Leukemia & Lymphoma. 53: 1105-12. PMID 22066713 DOI: 10.3109/10428194.2011.638717  1
2011 Thompson CA, Maurer MJ, Allmer C, Slager SL, Yost KJ, Macon WR, Ansell SM, Inwards DJ, Habermann TM, Link BK, Cerhan JR. Quality of life (QOL) as a predictor of survival in aggressive non-Hodgkin lymphoma (NHL). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 8059. PMID 28023542 DOI: 10.1200/Jco.2011.29.15_Suppl.8059  0.01
2011 Thompson CA, Maurer MJ, Cerhan JR, Katzmann JA, Ansell SM, Habermann TM, Macon WR, Weiner GJ, Link BK, Witzig TE. Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. American Journal of Hematology. 86: 998-1000. PMID 22006790 DOI: 10.1002/ajh.22168  1
2011 Morton LM, Cerhan JR, Hartge P, Vasef MA, Neppalli VT, Natkunam Y, Dogan A, Dave BJ, Jain S, Levy R, Lossos IS, Cozen W, Davis S, Schenk MJ, Maurer MJ, et al. Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era. International Journal of Molecular Epidemiology and Genetics. 2: 245-52. PMID 21915363  1
2011 Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, et al. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica. 96: 1619-26. PMID 21791475 DOI: 10.3324/Haematol.2011.049551  1
2011 Maurer MJ, Cerhan JR, Katzmann JA, Link BK, Allmer C, Zent CS, Call TG, Rabe KG, Hanson CA, Kay NE, Slager SL, Witzig TE, Shanafelt TD. Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. Blood. 118: 2821-6. PMID 21765023 DOI: 10.1182/Blood-2011-04-349134  1
2011 Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, Porrata LF, Johnston PB, Colgan JP, Markovic SN, Nowakowski GS, Thompson CA, Allmer C, Maurer MJ, Gupta M, et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 118: 4882-9. PMID 21725056 DOI: 10.1182/Blood-2011-02-334904  1
2011 Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, Perez DG, Soori GS, Link BK, Habermann TM, Witzig TE. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 118: 4053-61. PMID 21673350 DOI: 10.1182/blood-2011-02-336990  1
2011 Maurer MJ, Micallef IN, Cerhan JR, Katzmann JA, Link BK, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, Ansell SM, Porrata LF, Johnston PB, Nowakowski GS, Thompson CA, Gupta M, et al. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1620-6. PMID 21383282 DOI: 10.1200/JCO.2010.29.4413  1
2011 Shanafelt TD, Drake MT, Maurer MJ, Allmer C, Rabe KG, Slager SL, Weiner GJ, Call TG, Link BK, Zent CS, Kay NE, Hanson CA, Witzig TE, Cerhan JR. Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 117: 1492-8. PMID 21048153 DOI: 10.1182/Blood-2010-07-295683  1
2010 Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN, Kelly JL, Macon WR, Nowakowski GS, Inwards DJ, Johnston PB, Singh RJ, Allmer C, Slager SL, Weiner GJ, et al. Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4191-8. PMID 20713849 DOI: 10.1200/Jco.2010.28.6674  1
2010 Durnick DK, Law ME, Maurer MJ, Natkunam Y, Levy R, Lossos IS, Kurtin PJ, McPhail ED. Expression of LMO2 is associated with t(14;18)/IGH-BCL2 fusion but not BCL6 translocations in diffuse large B-cell lymphoma. American Journal of Clinical Pathology. 134: 278-81. PMID 20660332 DOI: 10.1309/AJCPATUP1D0HGCUG  1
2010 Geyer SM, Morton LM, Habermann TM, Allmer C, Davis S, Cozen W, Severson RK, Lynch CF, Wang SS, Maurer MJ, Hartge P, Cerhan JR. Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: A population-based study Cancer. 116: 2993-3000. PMID 20564404 DOI: 10.1002/Cncr.25114  1
2010 Thomas A, Gingrich RD, Smith BJ, Jacobus L, Ristow K, Allmer C, Maurer MJ, Habermann TM, Link BK. 18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of 'indeterminate' reports. Leukemia & Lymphoma. 51: 439-46. PMID 20141442 DOI: 10.3109/10428190903560198  1
2010 Goode EL, Maurer MJ, Sellers TA, Phelan CM, Kalli KR, Fridley BL, Vierkant RA, Armasu SM, White KL, Keeney GL, Cliby WA, Rider DN, Kelemen LE, Jones MB, Peethambaram PP, et al. Inherited determinants of ovarian cancer survival. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 995-1007. PMID 20103664 DOI: 10.1158/1078-0432.Ccr-09-2553  1
2010 Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, Hartmann LC, Disis ML, Ferrone S, Ishioka G, Knutson KL. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 825-34. PMID 20103660 DOI: 10.1158/1078-0432.Ccr-09-2781  1
2010 Nowakowski GS, Maurer MJ, Habermann TM, Ansell SM, Macon WR, Ristow KM, Allmer C, Slager SL, Witzig TE, Cerhan JR. Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 412-7. PMID 20008638 DOI: 10.1200/JCO.2009.23.4245  1
2010 Karyampudi L, Krco CJ, Kalli KR, Erskine CL, Hartmann LC, Goodman K, Ingle JN, Maurer MJ, Nassar A, Yu C, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, et al. Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. Cancer Immunology, Immunotherapy : Cii. 59: 161-71. PMID 19621224 DOI: 10.1007/S00262-009-0738-Z  1
2010 Nowakowski GS, Witzig TE, Maurer MJ, Cerhan JR. Reply to J.R. Carver et al. Journal of Clinical Oncology. 28: e612. DOI: 10.1200/JCO.2010.30.2752  1
2010 Nowakowski GS, Maurer MJ, Witzig TE, Cerhan JR. Reply to C. Barker et al and H. Asai et al Journal of Clinical Oncology. 28: e427-e428. DOI: 10.1200/JCO.2010.28.9710  1
2010 Wilcox RA, Baro XF, Porrata LF, Kwon ED, Maurer MJ, Micallef IN, Witzig TE, Ansell SM. Association of serum B7-H1 level and lymphopenia in diffuse large B-cell non-Hodgkin lymphoma. Journal of Clinical Oncology. 28: 8080-8080. DOI: 10.1200/Jco.2010.28.15_Suppl.8080  0.01
2009 Micallef IN, Maurer MJ, Nikcevich DA, Cannon MW, Schaefer EW, Moore DF, Kurtin P, Witzig TE. Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8508. PMID 27960859 DOI: 10.1200/Jco.2009.27.15_Suppl.8508  0.01
2009 Habermann TM, Thompson CA, LaPlant BR, Bauer BA, Janney CA, Clark MM, Rummans TA, Maurer MJ, Sloan JA, Geyer SM, Cerhan JR. Complementary and alternative medicine use among long-term lymphoma survivors: a pilot study. American Journal of Hematology. 84: 795-8. PMID 19894247 DOI: 10.1002/Ajh.21554  1
2009 Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF, et al. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2052-8. PMID 19307505 DOI: 10.1200/Jco.2008.19.0694  1
2009 Wang SS, Maurer MJ, Morton LM, Habermann TM, Davis S, Cozen W, Lynch CF, Severson RK, Rothman N, Chanock SJ, Hartge P, Cerhan JR. Polymorphisms in DNA repair and one-carbon metabolism genes and overall survival in diffuse large B-cell lymphoma and follicular lymphoma. Leukemia. 23: 596-602. PMID 18830263 DOI: 10.1038/Leu.2008.240  1
2009 Smallwood JA, Causey MF, Mossop DH, Klucsarits JR, Robertson B, Robertson S, Mason J, Maurer MJ, Melvin RJ, Dawson RD, Bortolotti GR, Parrish JW, Breen TF, Boyd K. Why are American Kestrel (Falco sparverius) populations declining in North America? Evidence from nest-box programs Journal of Raptor Research. 43: 274-282. DOI: 10.3356/Jrr-08-83.1  1
2009 Maurer MJ, Bank DH, Soukhojak AN, Sehanobish K, Khopkar A, Sharma S, Shembekar P. Computational fluid dynamics modeling of latent heat discharge in a macro-encapsulated phase change material device 7th International Energy Conversion Engineering Conference 1
2008 Racila E, Link BK, Weng WK, Witzig TE, Ansell S, Maurer MJ, Huang J, Dahle C, Halwani A, Levy R, Weiner GJ. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 6697-703. PMID 18927313 DOI: 10.1158/1078-0432.CCR-08-0745  1
2008 Metzger MB, Maurer MJ, Dancy BM, Michaelis S. Degradation of a cytosolic protein requires endoplasmic reticulum-associated degradation machinery. The Journal of Biological Chemistry. 283: 32302-16. PMID 18812321 DOI: 10.1074/Jbc.M806424200  1
2008 Habermann TM, Wang SS, Maurer MJ, Morton LM, Lynch CF, Ansell SM, Hartge P, Severson RK, Rothman N, Davis S, Geyer SM, Cozen W, Chanock SJ, Cerhan JR. Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma patients in the pre-rituximab era Blood. 112: 2694-2702. PMID 18633131 DOI: 10.1182/Blood-2007-09-111658  1
2008 Kalli KR, Krco CJ, Hartmann LC, Goodman K, Maurer MJ, Yu C, Johnson EM, Erskine CL, Disis ML, Wettstein PJ, Fikes JD, Beebe M, Ishioka G, Knutson KL. An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Research. 68: 4893-901. PMID 18559537 DOI: 10.1158/0008-5472.Can-07-6726  1
2008 Okuno SH, Delaune R, Sloan JA, Foster NR, Maurer MJ, Aubry MC, Rowland KM, Soori GS, Nikcevich DA, Kardinal CG, Northfelt DW, Adjei AA. A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. Cancer. 112: 1772-9. PMID 18224661 DOI: 10.1002/cncr.23313  1
2008 Micallef IN, Maurer MJ, Nikcevich DA, Cannon M, Moore DF, Kurtin P, Witzig TE. A phase II study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma Journal of Clinical Oncology. 26: 8500-8500. DOI: 10.1200/Jco.2008.26.15_Suppl.8500  0.01
2007 Cerhan JR, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W, Morton LM, Davis S, Severson RK, Rothman N, Lynch CF, Wacholder S, Chanock SJ, Habermann TM, Hartge P. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival Blood. 109: 5439-5446. PMID 17327408 DOI: 10.1182/Blood-2006-11-058040  1
2007 Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Giannini C, Hardwick JS, Moore DF, Zwiebel JA, Buckner JC. N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM) Journal of Clinical Oncology. 25: 2004-2004. DOI: 10.1200/Jco.2007.25.18_Suppl.2004  0.01
2006 Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer. 107: 2826-32. PMID 17099879 DOI: 10.1002/cncr.22342  1
2006 Ansell SM, Geyer SM, Maurer MJ, Kurtin PJ, Micallef INM, Stella P, Etzell P, Novak AJ, Erlichman C, Witzig TE. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients Clinical Cancer Research. 12: 6056-6063. PMID 17062681 DOI: 10.1158/1078-0432.CCR-06-1245  1
2006 Galanis E, Buckner JC, Maurer MJ, Sykora R, Castillo R, Ballman KV, Erickson BJ. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro-Oncology. 8: 156-65. PMID 16533757 DOI: 10.1215/15228517-2005-005  1
2006 Brown PD, Ballman KV, Rummans TA, Maurer MJ, Sloan JA, Boeve BF, Gupta L, Tang-Wai DF, Arusell RM, Clark MM, Buckner JC. Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. Journal of Neuro-Oncology. 76: 283-91. PMID 16163448 DOI: 10.1007/s11060-005-7020-9  1
2005 Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larson TS, Walker RC, Ansell SM, Macon WR, Gores GG, Stegall MD, McGregor CG. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders Journal of Clinical Oncology. 23: 7574-7582. PMID 16186599 DOI: 10.1200/JCO.2005.01.0934  1
2005 Brown PD, Maurer MJ, Rummans TA, Pollock BE, Ballman KV, Sloan JA, Boeve BF, Arusell RM, Clark MM, Buckner JC. A prospective study of quality of life in adults with newly diagnosed high-grade gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery. 57: 495-504; discussion . PMID 16145528 DOI: 10.1227/01.NEU.0000170562.25335.C7  1
2005 Galanis E, Buckner JC, Maurer MJ, Reid JM, Kuffel MJ, Ames MM, Scheithauer BW, Hammack JE, Pipoly G, Kuross SA. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: a North Central Cancer Treatment Group trial. Investigational New Drugs. 23: 495-503. PMID 16133802 DOI: 10.1007/S10637-005-2910-4  1
2005 Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5294-304. PMID 15998902 DOI: 10.1200/Jco.2005.23.622  1
2005 Ransom JE, Siler B, Peters RM, Maurer MJ. Worry: women's experience of HIV testing. Qualitative Health Research. 15: 382-93. PMID 15761106 DOI: 10.1177/1049732304271756  1
2005 Rao RD, Krishnan S, Fitch TR, Schomberg PJ, Dinapoli RP, Nordstrom K, Scheithauer B, O'Fallon JR, Maurer MJ, Buckner JC. Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. International Journal of Radiation Oncology, Biology, Physics. 61: 380-6. PMID 15667956 DOI: 10.1016/J.Ijrobp.2004.06.258  1
2005 Witzig TE, Ansell SM, Geyer SM, Kurtin PJ, Rowland KM, Flynn PJ, Morton RF, Dakhil SR, Gross HM, Maurer MJ, Kaufmann SH. Anti-tumor activity of low-dose single agent CCI-779 for relapsed mantle celllLymphoma: A phase II trial in the North Central Cancer Treatment Group Journal of Clinical Oncology. 23: 6504-6504. DOI: 10.1200/Jco.2005.23.16_Suppl.6504  0.01
2005 Galanis E, Buckner JC, Maurer MJ, Hidalgo M, Kreisberg JI, Peralba J, Jenkins RB, Walsh DJ. N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis Journal of Clinical Oncology. 23: 1505-1505. DOI: 10.1200/Jco.2005.23.16_Suppl.1505  0.01
2004 Brown PD, Ballman KV, Rummans TA, Maurer MJ, Sloan JA, Boeve BF, Arusell RM, Clark MM, Buckner JC. Prospective NCCTG quality of life (QOL) study in adult newly diagnosed high-grade gliomas (HGG). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1524. PMID 28015428 DOI: 10.1200/Jco.2004.22.14_Suppl.1524  0.01
2004 Galanis E, Buckner JC, Maurer M, Ballman K, Hidalgo M, Kreisberg JI, Boni J, James CD, Jenkins RB, Walsh DJ. NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1503. PMID 28015387 DOI: 10.1200/Jco.2004.22.90140.1503  0.01
2004 Micallef IN, Kahl BS, Gayko U, Cesano A, Ansell SM, Geyer S, Inwards DJ, Maurer MJ, Horning S, Habermann TM. Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL) Journal of Clinical Oncology. 22: 6580-6580. DOI: 10.1200/Jco.2004.22.90140.6580  0.01
2002 Wu LA, Kottke TE, Friedman PA, Luria DM, Grill DE, Maurer MJ. Implantable cardioverter defibrillator implantation rates in the Olmsted County, Minnesota, population: 1989-1999. Journal of Clinical Epidemiology. 55: 458-61. PMID 12007548 DOI: 10.1016/S0895-4356(01)00511-X  1
2000 Suh KW, Park CP, Maurer MJ, Tusim MH, De Genova R, Broos R, Sophiea DP. Lightweight cellular plastics Advanced Materials. 12: 1779-1789. DOI: 10.1002/1521-4095(200012)12:23<1779::AID-ADMA1779>3.0.CO;2-3  1
1998 Curiel RE, Mason KM, Dryden TD, Maurer MJ, Bigley NJ. Cytokines produced early in picornavirus infection reflect resistance or susceptibility to disease. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 18: 587-96. PMID 9726440  1
1992 Tyler GL, Simpson RA, Maurer MJ, Holmann E. Scattering properties of the Venusian surface: preliminary results from Magellan Journal of Geophysical Research. 97: 13,115-13,139.  1
1991 Krisher TP, Anderson JD, Morabito DD, Asmar SW, Borutzki SE, Delitsky ML, Densmore AC, Eshe PM, Lewis GD, Maurer MJ, Roth DC, Son YH, Spilker TR, Sweetnam DN, Taylor AH, et al. Radio range measurements of coronal electron densities at 13 and 3.6 centimeter wavelengths during the 1988 solar conjunction of Voyager 2 Astrophysical Journal. 375: L57-L60.  1
1987 Juni E, Heym GA, Maurer MJ, Miller ML. Combined genetic transformation and nutritional assay for identification of Moraxella nonliquefaciens. Journal of Clinical Microbiology. 25: 1691-4. PMID 3654942  1
1981 Thirumoorthi MC, Dajani AS, Vincent CV, Maurer MJ. Pharmacology, Safety, and efficacy of cefamandole in childhood infections. Antimicrobial Agents and Chemotherapy. 20: 21-4. PMID 7283413  1
1980 Dajani AS, Maurer MJ. Is Yersinia enterocolitica gastroenteritis a Canadian disease? The Journal of Pediatrics. 97: 165-6. PMID 7381642 DOI: 10.1016/S0022-3476(80)80171-5  1
1980 Anderson KC, Maurer MJ, Dajani AS. Pneumococci relatively resistant to penicillin: a prevalence survey in children. The Journal of Pediatrics. 97: 939-41. PMID 6904489 DOI: 10.1016/S0022-3476(80)80426-4  1
1973 Maurer MJ, Thompson HA. NON-FOURIER EFFECTS AT HIGH HEAT FLUX Journal of Heat Transfer, Transactions Asme. 95: 284-286.  1
1969 Maurer MJ. Relaxation model for heat conduction in metals Journal of Applied Physics. 40: 5123-5130. DOI: 10.1063/1.1657362  1
Show low-probability matches.